Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating That the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

GlobeNewswireMar 4 08:00 ET

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating From Lucid Capital Markets

BusinesswireFeb 27 10:43 ET

Lucid Capital Initiates Nuvectis Pharma(NVCT.US) With Buy Rating, Announces Target Price $18

Moomoo NewsFeb 26 07:31 ET · Ratings

Nuvectis Pharma | 10-K: FY2024 Annual Report

SECFeb 25 16:06 ET · Announcements

H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Cuts Target Price to $11

Moomoo NewsFeb 25 12:31 ET · Ratings

Nuvectis Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesFeb 25 11:57 ET · Ratings